A Phase I Pilot Study Comparing 123I MIP 1072 Versus 111In Capromab Pendetide in Subjects With Metastatic Prostate Cancer

NCT00992745 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: 123-I-MIP-1072
DRUG: 111-In capromab pendetide
DRUG: 123-I-MIP-1072

Sponsor

Molecular Insight Pharmaceuticals, Inc.